Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline : GSK on track with consumer split as buyout report boosts shares

10/12/2021 | 08:31am EDT
FILE PHOTO: A GlaxoSmithKline plant is seen in Montrose, Scotland, Britain

(Reuters) - GlaxoSmithKline is "firmly on track" to spin off its consumer health business next year, the British drugmaker said on Tuesday, after Bloomberg News reported the unit could attract bids from private equity firms such as Advent, CVC and KKR.

The division, which makes Sensodyne toothpaste, and Advil and Panadol painkillers, could also draw interest from big pharmaceutical and consumer goods companies, the report said , citing unidentified people with knowledge of the matter.

It added the unit could be valued at 40 billion pounds ($54 billion) or more.

A GSK spokesperson declined to comment on whether the company had received takeover interest in the division, a joint venture with U.S. drugmaker Pfizer.

The report sent London-listed GSK's shares as much as 4.8% higher to 1,460.2 pence.

"GSK is far advanced with its plan for the separation of Consumer Healthcare," the GSK representative said, adding the drugmaker was on course for the split in mid-2022.

The company set out plans in June to turn the consumer arm into a separately listed company to focus on its underperforming drugs business, and has defended those plans after activist investor Elliott suggested some changes including that GSK remained open to potentially selling the consumer business.

"The feedback we have received from our shareholders is that they are very keen to own the new Consumer Healthcare company as a listed entity through the demerger ... The GSK board will fulfil its fiduciary duties to evaluate any alternative options," GSK's spokesperson said.

Under GSK's plan, shareholders will receive stock in the new consumer health group amounting to at least 80% of the 68% stake that GSK currently owns in it. Pfizer owns the remaining 32%.

New GSK would sell the remaining 20% stake "in a timely manner," the group has said. Pfizer has also said it would seek to exit its shareholding.

Elliott, which in July confirmed holding a significant stake in GSK, said then that a conservative estimate would value GSK's shareholding in the consumer unit at about 34 billion pounds - working out to roughly 50 billion pounds overall.

Brokerage Jefferies has valued it at 45 billion pounds.

Another activist investor, Bluebell Capital Partners, which holds a smaller stake in GSK, said last month the consumer arm should attract interest from trade buyers and, potentially, private equity investors.

Elliott has said a sale of the unit to an industry peer would command a "meaningful premium" to its estimated value due to potential synergies of up to 10% of the business's revenues.

Separately, Bluebell said in an open letter to GSK Chairman Jonathan Symonds dated Oct. 11, that both he and Chief Executive Emma Walmsley should be replaced, voicing disappointment over an Oct. 7 investor event.

"We completely reject the content and claims made in this letter, which are not representative of the discussion at the meeting or the majority of our shareholders' views," GSK said in response.

(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger in Frankfurt; Editing by Bernadette Baum and Mark Potter)

By Pushkala Aripaka and Ludwig Burger

© Reuters 2021
10/20GLAXOSMITHKLINE : Shingles Vaccine Receives Recommendation in US for Immunocompromised Adu..
10/20GLAXOSMITHKLINE : US Centers for Disease Control and Prevention's Advisory Committee on Im..
10/20GLAXOSMITHKLINE : Viom, GlaxoSmithKline Expand Collaboration Into New Cancer, Autoimmune D..
10/20LESS TALK, MORE ACTION : New report sponsored by ViiV Healthcare provides roadmap to achie..
10/19'Green is good' says UK's Johnson, wooing Wall Street dollars
10/19Pharnext renforce son équipe de direction avec trois nominations clés pour poursuivre l..
10/19Pharnext strengthens its management team with three key appointments to support ongoing..
10/18GLAXOSMITHKLINE : GSK to showcase significant scientific advances in renal care at the Ame..
10/18Today on Wall Street: This is the real test
10/18GLAXOSMITHKLINE : Berenberg Slashes GlaxoSmithKline's PT, Keeps Rating
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Sales 2021 33 519 M 46 262 M 46 262 M
Net income 2021 3 787 M 5 226 M 5 226 M
Net Debt 2021 21 074 M 29 085 M 29 085 M
P/E ratio 2021 18,5x
Yield 2021 5,68%
Capitalization 70 480 M 97 422 M 97 275 M
EV / Sales 2021 2,73x
EV / Sales 2022 2,56x
Nbr of Employees 94 066
Free-Float 92,3%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 1 408,20 GBX
Average target price 1 602,73 GBX
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.07%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.14.34%239 966
NOVO NORDISK A/S56.26%238 738